Washington’s Prescription Drug Program U sing systematic reviews to make policy decisions in the effort to contain prescription drug expenditures Siri.

Slides:



Advertisements
Similar presentations
Prescription Drug Purchasing Consortium Performance Audit Proposed Final Report Joint Legislative Audit and Review Committee October 22, 2008 John Bowden,
Advertisements

Management of Drug Formulary Dimitry Gotlinsky Western University Managed Care Clerkship ProPharma Pharmaceutical Consultants, Inc. 06/16/06.
Dr. John E. Niederhuber Director, National Cancer Institute Board of Scientific Advisors June 22, 2009 NCI Director’s Update.
EFFECTIVE PREFERRED DRUG LISTS National State Attorneys General Program of Columbia Law School Presented by J. Kevin Gorospe, Pharm.D. Chief, Pharmacy.
SLOWING THE GROWTH OF MEDICAID SPENDING IN VIRGINIA STRATEGIES DESIGNED TO CONTROL CHILDREN’S MENTAL HEALTH SERVICES EXPENDITURES.
1 The Florida International University Faculty Senate Meeting Operating Budget FY07-08 & Budget Reduction Plan September 18, 2007.
Oregon EPC DRUG EFFECTIVENESS REVIEW PROJECT Methods for Comparative Evidence Reviews September 2005 Oregon Evidence-based Practice Center for the Drug.
1 District of Columbia Medical Assistance Administration Expedited Prior Authorization Pharmacy Guidance NOTE: As of October 1, 2008, the Medical Assistance.
1 ADHD and AAP Drug Safety Standards for Medicaid Children Health and Recovery Services Administration (HRSA) Dr. Jeffrey Thompson, Medical Director Fee-for-Service.
Office of the Auditor General of Canada The State of Program Evaluation in the Canadian Federal Government Glenn Wheeler Director, Results Measurement.
Basic Health Plan: Part 1 Preliminary Report Joint Legislative Audit and Review Committee Cynthia L. Forland Lisa Jeremiah November 30, 2005.
Paying Less By Purchasing Smarter Gerard Anderson, PhD Professor Johns Hopkins University.
1 Evidence-based Medicine and the Drug Effectiveness Review Project: States Using Research in Quest for Improved Pharmaceutical Value Attorneys General.
1 State Perspectives on Medicare Part D: Lessons from Pharmacy Plus Programs Cindy Parks Thomas Donald Shepard Christine E. Bishop Daniel M. Gilden Brandeis.
Department of Public Health and Preventive Medicine Systematic Reviews of Drugs Within Classes: Bringing Clinical Evidence to State Policy Makers NAMI.
Karmen Hanson, MA Senior Policy Specialist National Conference of State Legislatures 340B Drug Purchasing: Options for States Overview of State Rx & 340B.
Drug Cost Containment National Governor’s Association Health Policy Advisors Meeting September 3-5, 2003 Mark Gibson Program Officer, Milbank Memorial.
National e-Prescribing Conference Sponsored by CMS and Industry Partners - October 6 & 7, 2008 Florida Agency for Health Care Administration Florida Center.
COMPARATIVE EFFECTIVENESS RESEARCH AND THE CALIFORNIA MEDI-CAL PROGRAM Len Finocchio, Dr.P.H Associate Director California Department of Health Care Services.
Status Report on Development of a Medicaid Preferred Drug List Program Presentation to: The Joint Commission on Health Care Patrick W. Finnerty Department.
Evidence-Based Medicine: Making Today’s Goals Tomorrow’s Reality Carolyn M. Clancy, MD Director Agency for Healthcare Research and Quality Washington,
DEPARTMENT OF JUVENILE JUSTICE OPERATING BUDGET DEFICIT Wansley Walters, Secretary Rick Scott, Governor SENATE CRIMINAL JUSTICE COMMITTEE October.
Systematic Reviews of Drugs within Classes: Policy Makers in Search of Evidence Philadelphia, Pennsylvania October 8, 2004.
K-12 School Spending and Performance Review Preliminary Report Joint Legislative Audit & Review Committee September 14, 2005 Stephanie Hoffman and Lisa.
Michigan Medicaid Pharmacy Cost Containment Paul Reinhart, Director Medical Services Administration Michigan Department of Community Health October 8,
REPORT ON THE MINISTERIAL TASK TEAM REVIEW OF MEDICINES CONTROL COUNCIL AND RECOMMENDATIONS ON THE NEW REGULATORY AUTHORITY PRESENTATION TO HEALTH PORTFOLIO.
Florida Agency for Health Care Administration Florida Center for Health Information and Policy Analysis Florida Public Health Association - Medical Director’s.
Overview of the Communication Plan for the Virginia Medicaid Preferred Drug List Program Presentation to: PDL/PA Implementation Advisory Group Cheryl J.
OREGON’S APPROACH TO PRESCRIPTION DRUGS John Santa, M.D. Administrator Office of Oregon Health Policy and Research.
Fee For Service Program Alabama Medicaid Program Changes.
1 Comparative Effectiveness Research: Key Issues and Controversies Consumer-Purchaser Disclosure Project Discussion Forum May 5, 2009 Steven D. Pearson,
Supporting Informed Formulary Decision Making: CADTH’s Common Drug Review Denis Bélanger, Director, CADTH New Brunswick Stroke Summit November 27, 2010,
Department of Public Health and Preventive Medicine Drug Effectiveness Review Project: States Working Together to Find Best Available Evidence The National.
Roles of DMAS, Pharmacy & Therapeutics Committee, and Preferred Drug List Contractor Presentation to: The Medicaid Pharmacy & Therapeutics Committee Patrick.
System Wide Strategies: Controlling Costs in Medicaid Brendan Krause National Governors Association Illinois Health Forum Wednesday, December 7, 2005.
Green Mountain Care A projection of estimated costs and funding sources Presented by Wendy Wilton May
ASPECTS AFFECTING THE HOSPITAL OPERATION Financial Financial Operational Operational Administrative Administrative Clinical Clinical Safety Safety.
Evaluation of Virginia’s Preferred Drug List: 2 nd Quarter Interim Report Policy and Research Division June 22, 2004Department of Medical Assistance Services.
FY2010 and FY2011 Update Board of Early Education and Care June 8, 2010.
Status Report on Development of a Medicaid Preferred Drug List Program Presentation to: The Medicaid Pharmacy & Therapeutics Committee Cynthia B. Jones.
Medicaid Fee-for-Service: Prior Authorization Criteria & the Role of the DUR Board Charles Agte, Pharmacy Administrator Health Care Services June 19, 2013.
It’s not just a Preferred Drug List… It’s the Transformation of the Virginia Medicaid Pharmacy Program Bryan Tomlinson Department of Medical Assistance.
Retiree Medical Insurance Plan Financial Health of the Plan James Clagett, HRSCM May 29, 2009.
September Board Meeting FY08 and FY09 Spending Plan.
Summary Pattern of Specific COX II Inhibitors Use Physician prescribed appropriate COX II use in high risk was 40.08% and inappropriate COX II use in low.
340B In New Mexico Senator Dede Feldman New Mexico State Legislature 8/5/05.
Helen Burstin, MD, MPH Director, Center for Primary Care Research Agency for Healthcare Research and Quality April 16, 2001 The Effect of Working Conditions.
Confidential and Proprietary Information © 2014 Express Scripts Holding Company. All Rights Reserved. 1 Confidential and Proprietary Information © 2014.
University of Michigan Health System Children with Special Health Care Needs: Looking Back; Looking Forward Gary L. Freed, MD, MPH Director, Division of.
Evaluation of Virginia’s Preferred Drug List: 4th Quarter Report Policy and Research Division November 2, 2004Department of Medical Assistance Services.
Drug Formulary Development & Management
Budget Highlights, Health Care, and more.  Spends: $38.2 billion, representing a 12 percent increase from the last two-year budget cycle.  Ending-fund.
Comparative Effectiveness Research (CER) and Patient- Centered Outcomes Research (PCOR) Presentation Developed for the Academy of Managed Care Pharmacy.
DHS Health Care Services Study: Potential Coverage Strategies for the Non-Disabled Population Michael Bailit Bailit Health Purchasing, LLC March 18, 2004.
Prescription Medication Working Group Co-Chairs Katherine Murray and Tom Werner March 14, 2007.
Measuring UNLV’s Health: Faculty and Staff Tell Us Their Story May 30, Annual Forum Association for Institutional Research San Diego, California.
Pharmacy Costs Which Medications Offer Value And How Are They Priced.
Comparative Effectiveness Research: Key Issues and Controversies
Pharmacy & Therapeutics Committee
Pharmacy & Therapeutics Committee
Recovery Residences - Florida
To Entrust or Not to Entrust
Primum non nocere Olabisi Oshikanlu M.D., F.A.A.P
Using Evidence For Better Health Policy
Pharmacy & Therapeutics Committee
Federal Budget Process – Its Challenges as well as its Opportunities
Medicare Reform: Implications for Pharmaceutical Manufacturers
Drug Formulary Development & Management
Pharmacy & Therapeutics Committee
Presentation transcript:

Washington’s Prescription Drug Program U sing systematic reviews to make policy decisions in the effort to contain prescription drug expenditures Siri Childs, Pharm D Pharmacy Administrator, (Formerly) Health and Recovery Services Administration, Washington State AHRQ Annual Meeting Bethesda MD Sept 20, 2011

Siri Childs, Pharm D Pharmacy Administrator (formerly) Health and Recovery Services Administration Washington State Department of Social and Health Services Sept 20, The background October 2002: Washington signed original contract with Oregon Health Sciences University’s (OHSU) Evidence- based Practice Center (EPC) October 2003: Washington was one of 15 participating entities - including 13 other Medicaid States - in Oregon’s Drug Effectiveness Review Project Systematic reviews of the literature assisted evidence-based selections for a state Preferred Drug List (PDL) and Medicaid’s Drug Utilization Review Program

Siri Childs, Pharm D Pharmacy Administrator (Formerly) Health and Recovery Services Administration Washington State Department of Social and Health Services Sept 20, How it worked OHSU EPC provided the “evidence” via the drug- class reports to Washington Pharmacy and Therapeutics (P&T) Committee P&T Committee made recommendations to the agencies to make local decisions Actualization of Gov. Kitzhaber’s Project Slogan, “Globalized evidence, localized decision-making”

Siri Childs, Pharm D Pharmacy Administrator, (Formerly) Health and Recovery Administration Washington State Department of Social and Health Services Sept 20, Education OHSU EPC faculty trained P&T Committee members on the basics of systematic reviews comparing the safety, efficacy and effectiveness of drugs in the drug class reviews Delfini Group, LLC taught Washington agency staff and P&T Committee members how to read studies including evidence tables and how to interpret the quality of the evidence (only fair to good studies considered “useful”)

Siri Childs, Pharm D Pharmacy Administrator (Formerly) Health and Recovery Services Administration Washington State Department of Social and Health Services Sept 20, Key Factors to Success Enabling legislation: –State Senate Bill 6088 was passed by the 2003 Legislature to mandate an evidence-based Preferred Drug List for state agencies purchasing drugs for Washington residents and the formation of a P&T Committee Credible research: OHSU EPC and the Drug Effectiveness Project Continuing education: Delfini Group LLC conduct annual training to state agency decision makers and P&T Committee members

Siri Childs, Pharm D Pharmacy Administrator (Formerly) Health and Recovery Services Administration Washington State Department of Social and Health Services Sept 20, Successes Financial: –Preferred drugs: Savings estimated at $46million/year –Supplemental rebates: Savings estimated at $6.6 million/year –Pharmacy spend as a percent of Medicaid spend: Dropped 3.4% from FY 2005 to FY 2008 –Drug Utilization Review: Savings estimated at $24 million per year from targeted drug initiatives in the prior authorization program Clinical: –Vioxx: Evidence showed safety concerns; COX IIs not any more safe than older less expensive NSAIDS –Gabapentin: Evidence showed less efficacy than placebo for bipolar disorder –ACEI vs ARBs: Evidence showed similar efficacy and safety at lower cost for ACEI; ARBs dropped from PDL

Siri Childs, Pharm D Pharmacy Administrator Health and Recovery Services Administration Washington State Department of Social and Health Services Sept 20, Obstacles Initial prescriber resistance Drug manufacturers’ objections Lack of useful studies State budget

Contacts Oregon Health Science University EPC: Marian McDonagh, Pharm D, (503) Drug Effectiveness Review Project: Alison Little, MD, (503) Delfini Group LLC: Michael Stuart, MD or Sheri WA Medicaid Drug Program: Charles Agte, (360) Siri Childs, Pharm D Pharmacy Administrator (Formerly) Health and Recovery Services Administration Washington State Department of Social and Health Services Sept 20,2011 8

Questions? For more information: Siri Childs, Pharm D (360) Siri Childs, Pharm D PharmacyAdministrator (Formerly) Health and Reoovery Services Administration Washington State Department of Social and Health Services Sept 20,2011 9